ESMO 2024 Key Highlights in Liver Cancer: LEAP-012 and IMbrave050 Discussion

Richard Finn, MD, of the Geffen School of Medicine at UCLA, provides an update on recent developments in hepatocellular carcinoma treatment (HCC), highlighting key findings from studies involving immune checkpoint inhibitors targeting CTLA-4 and PD-1 pathways. Dr. Finn explains how the inclusion of patients with main portal vein invasion impacts outcomes in overall survival.